Thrombotic Thrombocytopenic Purpura (TTP) — Pathway
MAHA + thrombocytopenia, normal PT/APTT; with a high PLASMIC score, start plasma exchange + steroids without waiting for ADAMTS13; do not transfuse platelets.
High suspicion → plasma exchange: High suspicion — start without waiting for the ADAMTS13 result (after sampling): 1) plasma exchange (PEX, first-line, daily until platelets…
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).
Full pathway
- [Decision] PLASMIC / clinical probabilityPLASMIC score / high clinical suspicion of TTP? (Microangiopathic hemolytic anemia (MAHA) + thrombocytopenia with no other cause → suspect TTP (ADAMTS13 <10%). The pentad (+ neuro/renal/fever) is present in only ~10%. Labs: schistocytes, raised LDH, low haptoglobin, raised indirect bilirubin, normal PT/APTT (distinguishes from DIC), negative Coombs. PLASMIC score (platelets <30, hemolysis, no active cancer/transplant, MCV <90, INR <1.5, Cr <2.0) 6–7 = high risk.)
- High suspicion (PLASMIC 6–7 or clinical) → High suspicion → plasma exchange
- Low probability → Low probability
- [End] Low probabilityComplete ADAMTS13, repeat blood film/hemolysis markers; differentiate DIC (prolonged PT/APTT), HUS, HELLP, malignant hypertension and other thrombotic microangiopathies, and treat accordingly.
- [End] High suspicion → plasma exchangeHigh suspicion — start without waiting for the ADAMTS13 result (after sampling): 1) plasma exchange (PEX, first-line, daily until platelets recover). 2) High-dose corticosteroids. 3) Caplacizumab (anti-vWF, for acquired TTP). 4) Rituximab (acquired immune TTP). Do not transfuse platelets (unless life-threatening/intracranial bleeding — can worsen microthrombosis). ADAMTS13 <10% confirms; ≥20% look for another diagnosis. Hematology consult.
Source guidelines & references
- ISTH TTP diagnosis guideline (2020); PLASMIC score
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.